Five Prime Therapeutics Inc (FPRX): Marc Belsky , Senior Vice President and CFO of Five Prime Therapeutics Inc sold 34,102 shares on Apr 22, 2016. The Insider selling transaction was reported by the company on Apr 26, 2016 to the Securities and Exchange Commission. The shares were sold at $49.63 per share for a total value of $1,705,254.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 26, 2016, Franklin M Berger (director) purchased 5,000 shares at $49.54 per share price.On Apr 22, 2016, Lewis T Williams (President, CEO and Chairman) sold 48,671 shares at $48.03 per share price.Also, On Apr 8, 2016, Marc Belsky (Senior Vice President and CFO) sold 20,814 shares at $45.04 per share price.On Jan 29, 2016, Francis Willard Sarena (EVP, Gen Counsel & Secretary) sold 30,000 shares at $35.31 per share price.
Five Prime Therapeutics Inc: On Friday, Apr 22, 2016 heightened volatility was witnessed in Five Prime Therapeutics Inc which led to swings in the share price. The shares opened for trading at $48.9 and hit $50.11 on the upside , eventually ending the session at $49.76, with a gain of 1.70% or 0.83 points. The heightened volatility saw the trading volume jump to 5,74,052 shares. The 52-week high of the share price is $50.11 and the company has a market cap of $1,384 M . The 52-week low of the share price is at $14.7.
Five Prime Therapeutics Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include FPA008 FPA144 and FP-1039/GSK3052230. FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1) receptor (CSF1R) that the Company is developing in rheumatoid arthritis. FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b) which the Company is developing to treat patients with gastric cancer. FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation. Its partner GlaxoSmithKline is developing FP-1039/GSK3052230 to treat patients with squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.